Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic toll-like receptor 7/8 activation

OncoImmunology

Volumn 1, Issue 3, 2012, Pages 298-305

  Stathopoulos, Apostolis ^a,b   Pretto, Chrystel ^b   Devillers, Laurent ^b   Pierre, Denis ^b   Hofman, Florence M ^b,c   Kruse, Carol ^d   Jadus, Martin R ^e,f   Chen, Thomas C ^b,c   Schijns, Virgil E J C ^b,g  

^a Dept of Neurosurgery   (Belgium)

^b Epitopoietics Research Corporation (ERC)   (Belgium)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Brain tumor; Glioma; Immunotherapy; TLR agonist

Indexed keywords

CYCLOPHOSPHAMIDE; RESIQUIMOD;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; GLIOBLASTOMA; IMMUNOLOGICAL MEMORY; IN VIVO STUDY; INNATE IMMUNITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SECOND CANCER;

EID: 84885819087     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.19068     Document Type: Article

References (42)

1. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-4; http://dx.doi.org/10.1126/science.1129139
2. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998; 58:3491-4;
3. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-13; http://dx.doi.org/10.1056/NEJMoa020177
4. Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001; 61:5132-6;
5. Vesalainen S, Lipponen P, Talja M, Syrjanen K. Histological grade, perineural infiltration, tumourinfiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994; 30:1797-803; http://dx.doi.org/10.1016/0959-8049(94)E0159-2
6. Marrogi AJ, Munshi A, Merogi AJ, Ohadike Y, El-Habashi A, Marrogi OL. Freeman, S. M. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer 1997; 74:492-501; http://dx.doi.org/10.1002/(SICI)1097-0215(19971021)74:5,492::AID-IJC3.3. 0.CO;2-Z
7. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-8; http://dx.doi.org/10.1038/ni1102-991
8. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21:137-48; http://dx.doi.org/10.1016/j.immuni.2004.07.017
9. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998; 95:7556-61; http://dx.doi.org/10.1073/pnas.95.13.7556
10. Beckhove P, Feuerer M, Dolenc M, Schuetz F, Choi C, Sommerfeldt N, et al. Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest 2004; 114:67-76;
11. Hofman FM, Stathopoulos A, Kruse CA, Chen TC, Schijns VEJC. Immunotherapy of Malignant Gliomas Using Autologous and Allogeneic Tissue Cells. Anticancer Agents Med Chem 2010; 10:462-70;
12. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6:715-27; http://dx.doi.org/10.1038/nri1936
13. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115:3623-33; http://dx.doi.org/10.1172/JCI25947
14. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005; 8:369-80; http://dx.doi.org/10.1016/j.ccr.2005.10.012
15. Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL. A unique subset of CD4 +CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 2007; 13:4345-54; http://dx.doi.org/10.1158/1078-0432.CCR-07-0472
16. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410:1107-11; http://dx.doi.org/10.1038/35074122
17. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21:335-76; http://dx.doi.org/10.1146/annurev.immunol.21.120601.141126
18. Schijns VEJC, Lavelle EC. Trends in vaccine adjuvants. Expert Rev Vaccines 2011; 10:539-50; http://dx.doi.org/10.1586/erv.11.21
19. Gollnick H, Barona CG, Frank RG, Ruzicka T, Megahed M, Tebbs V, et al. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur J Dermatol 2005; 15:374-81;
20. Gaitanis G, Kalogeropoulos C, Bassukas ID. Imiquimod can be combined with cryosurgery (immunocryosurgery) for locally advanced perocular basal cell carcinomas. Br J Ophthalmol 2011; 95:890-2; http://dx.doi.org/10.1136/bjo.2010.195800
21. Gaspari A, Tyring SK, Rosen T. Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol 2009; 8:467-74;
22. Vasilakos JP, Smith RM, Gibson SJ, Lindh JM, Pederson LK, Reiter MJ, et al. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell Immunol 2000; 204:64-74; http://dx.doi.org/10.1006/cimm.2000.1689
23. Risini D, Weeratna RD, Shawn R. Makinen, McCluskie MJ, Davis HL. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine 2005; 23:5263-70; http://dx.doi.org/10.1016/j.vaccine.2005.06.024
24. Hamm S, Heit A, Koffler M, Huster KM, Akira S, Busch DH, et al. Immunostimulatory RNA is a potent inducer of antigen-specific cytotoxic and humoral immune response in vivo. Int Immunol 2007; 19:297-304; http://dx.doi.org/10.1093/intimm/dxl146
25. Xiong Z, Ohlfest JR. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors. J Immunother 2011; 34:264-9; http://dx.doi.org/10.1097/CJI.0b013e318209eed4
26. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002; 3:499; http://dx.doi.org/10.1038/ni0602-499
27. Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, Pluhar GE, et al. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol 2007; 85:133-48; http://dx.doi.org/10.1007/s11060-007-9400-9
28. Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset. Cancer Res 1987; 47:3317-21;
29. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8:59-73; http://dx.doi.org/10.1038/nri2216
30. Kempf RA, Mitchell MS. Effects of chemotherapeutic agents on the immune response. Cancer Invest 1984; 2:459-66; http://dx.doi.org/10.3109/07357908409048519
31. Kruse CA, Molleston MC, Parks EP, Schiltz PM, Kleinschmidt-DeMasters BK, Hickey WF. A rat glioblastoma model, CNS-1, with invasive characteristics similar to those of human gliomas: a comparison to 9L gliosarcoma. J Neurooncol 1994; 22:191-200; http://dx.doi.org/10.1007/BF01052919
32. Avril T, Vauleon E, Tanguy-Royer S, Mosser J, Quillien V. Mechanisms of immunomodulation in human glioblastoma. Immunotherapy 2011; 3(Suppl): 42-4; http://dx.doi.org/10.2217/imt.11.39
33. Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, et al. Immune resistence orchestrated by the tumor microenvirenment. Immunol Rev 2006; 213: 131-45; http://dx.doi.org/10.1111/j.1600-065X.2006.00442.x
34. Roszman T, Elliott L, Brooks W. Modulation of T-cell function by gliomas. Immunol Today 1991; 12:370-4; http://dx.doi.org/10.1016/0167-5699(91)90068-5
35. Ge L, Hoa N, Bota DA, Natividad J, Howat A, Jadus MR. Immunotherapy of brain cancers: the past, the present and future directions. Clin Dev Immunol 2010; 296453; Epub; http://dx.doi.org/10.1155/2010/296453
36. Cherfils-Vicini J, Platonova S, Gillard M, Laurans L, Validire P, Caliandro R, et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest 2010; 120:1285-97; http://dx.doi.org/10.1172/JCI36551
37. Kruse CA, Mitchell DH, Kleinschmidt-DeMasters BK, Bellgrau D, Eule JM, Parra JR, et al. Systemic Chemotherapy Combined with Local Adoptive Immunotherapy Cures Rats Bearing 9L Gliosarcoma. J Neurooncol 1993; 15:97-112; http://dx.doi.org/10.1007/BF01053931
38. Gomez GG, Hutchison R, Kruse CA. Chemoimmunotherapy and chemo- adoptive immunotherapy of cancer. Cancer Treat Rev 2001; 27:375-402;
39. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Sting G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 2007; 204:1441-51; http://dx.doi.org/10.1084/jem.20070021
40. Soria I, Myhre P, Horton V, Ellefson P, McCarville S, Schmitt K, et al. Effect of food on the pharmacokinetics and bioavailability of oral imiquimod relative to a subcutaneous dose. Int J Clin Pharmacol Ther 2000; 38:476-81;
41. Westfall B, Sitaraman K, Solus J, Hughes J, Rashtchian A. High specificity and robustness of AccuPrimeTM Taq provides the ideal tool for demanding miniaturized, multiplex, and high-throughput PCR. Focus 1997; 19:46.
42. Xiong Z, Ohlfest J. Topical Imiquimod has therapeutic and immunomodulaotory effects against intracranialt tumors. J Immunother 2011; 34:264-9; http://dx.doi.org/10.1097/CJI.0b013e318209eed4